Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
1.
J Biochem Mol Toxicol ; 37(5): e23317, 2023 May.
Article in English | MEDLINE | ID: mdl-36872850

ABSTRACT

Early brain injury (EBI) is associated with the adverse prognosis of subarachnoid hemorrhage (SAH) patients. The key bioactive component of the Chinese herbal medicine Artemisia asiatica Nakai (Asteraceae) is eupatilin. Recent research reports that eupatilin suppresses inflammatory responses induced by intracranial hemorrhage. This work is performed to validate whether eupatilin can attenuate EBI and deciphers its mechanism. A SAH rat model was established by intravascular perforation in vivo. At 6 h after SAH in rats, 10 mg/kg eupatilin was injected into the rats via the caudal vein. A Sham group was set as the control. In vitro, BV2 microglia was treated with 10 µM Oxyhemoglobin (OxyHb) for 24 h, followed by 50 µM eupatilin treatment for 24 h. The SAH grade, brain water content, neurological score, and blood-brain barrier (BBB) permeability of the rats were measured 24 h later. The content of proinflammatory factors was detected via enzyme-linked immunosorbent assay. Western blot analysis was conducted to analyze the expression levels of TLR4/MyD88/NF-κB pathway-associated proteins. In vivo, eupatilin administration alleviated neurological injury, and decreased brain edema and BBB injury after SAH in rats. Eupatilin markedly reduced the levels of interleukin-1ß (IL-1ß), IL-6, and tumor necrosis factor-α (TNF-α), and suppressed the expression levels of MyD88, TLR4, and p-NF-κB p65 in the SAH rats' cerebral tissues. Eupatilin treatment also reduced the levels of IL-1ß, IL-6, and TNF-α, and repressed the expression levels of MyD88, TLR4, and p-NF-κB p65 in OxyHb-induced BV2 microglia. Additionally, pyrrolidine dithiocarbamate or resatorvid enhanced the suppressive effects of eupatilin on OxyHb-induced inflammatory responses in BV2 microglia. Eupatilin ameliorates SAH-induced EBI via modulating the TLR4/MyD88/NF-κB pathway in rat model.


Subject(s)
Brain Injuries , Subarachnoid Hemorrhage , Rats , Animals , NF-kappa B/metabolism , Subarachnoid Hemorrhage/drug therapy , Subarachnoid Hemorrhage/complications , Subarachnoid Hemorrhage/metabolism , Myeloid Differentiation Factor 88/metabolism , Signal Transduction , Rats, Sprague-Dawley , Tumor Necrosis Factor-alpha/metabolism , Toll-Like Receptor 4/metabolism , Interleukin-6/metabolism , Brain Injuries/metabolism
2.
J Cancer Res Ther ; 17(3): 619-624, 2021 Jul.
Article in English | MEDLINE | ID: mdl-34269290

ABSTRACT

BACKGROUND: Portal vein tumor thrombus (PVTT) remains a poor prognostic factor occurring in about 10%-40% of patients with hepatocellular carcinoma (HCC) for the optimal treatment is controversial. Anlotinib is an novel small molecule inhibitor that has a broad spectrum of inhibitory activities on tumor angiogenesis and growth. However, so far, no studies have reported the use of anlotinib in the treatment of HCC patients with PVTT. Here, we evaluated the safety and efficacy of anlotinib, followed by transarterial chemoembolization (TACE) and radiofrequency ablation (RFA) for the treatment of patients with HCC and PVTT. MATERIALS AND METHODS: A total of 145 consecutive HCC patients who underwent TACE in combination with RFA were enrolled in the retrospective study. Twenty-eight patients were diagnosed with PVTT and received anlotinib as basic treatment. The adverse events (AEs) were graded according to the National Cancer Institute Common Terminology Criteria for AEs Version 4.0. Time to tumor progression (TTP) and overall survival (OS) were calculated using the Kaplan-Meier method. RESULTS: The most common toxicities related to anlotinib were pharyngalgia (53.6%), fatigue (42.9%), and hand-foot skin reaction (39.3%). The median OS was 13 months (range: 3-18 months) with 1-year OS rate of 64.3%. The median TTP was 7 months (range: 1-12 months) with 6-month rate of 46.4%. CONCLUSION: Anlotinib followed by TACE and RFA is a safe and effective initial treatment modality for HCC patients with PVTT. Anlotinib may be a promising therapeutic option for relieving and/or stabilizing HCC with PVTT.


Subject(s)
Carcinoma, Hepatocellular/therapy , Catheter Ablation/methods , Chemoembolization, Therapeutic/methods , Indoles/administration & dosage , Liver Neoplasms/therapy , Quinolines/administration & dosage , Venous Thrombosis/therapy , Carcinoma, Hepatocellular/complications , Carcinoma, Hepatocellular/mortality , Carcinoma, Hepatocellular/pathology , Catheter Ablation/adverse effects , Chemoembolization, Therapeutic/adverse effects , Combined Modality Therapy/adverse effects , Combined Modality Therapy/methods , Female , Follow-Up Studies , Humans , Indoles/adverse effects , Kaplan-Meier Estimate , Liver Neoplasms/complications , Liver Neoplasms/mortality , Liver Neoplasms/pathology , Male , Neoplasm Invasiveness/pathology , Portal Vein/pathology , Portal Vein/surgery , Postoperative Complications/epidemiology , Postoperative Complications/etiology , Quinolines/adverse effects , Retrospective Studies , Sorafenib/administration & dosage , Sorafenib/adverse effects , Survival Rate , Venous Thrombosis/etiology , Venous Thrombosis/mortality
3.
Br J Nutr ; 118(6): 431-440, 2017 Sep.
Article in English | MEDLINE | ID: mdl-28980891

ABSTRACT

Anaemia during pregnancy, characterised by Hb <110 g/l, is a specific risk factor for adverse maternal and perinatal outcomes in developing countries. The objective of this study was to determine the effectiveness of daily antenatal supplementation with multiple micronutrients (MMN) compared with folic acid (FA) on the occurrence of anaemia among pregnant women and their infants' health in a high-altitude area. A prospective cohort study was carried out in two rural counties in Tibet from 2007 to 2012. A total of 1149 eligible pregnant women were allocated daily supplementation with FA in one county and MMN containing a recommended allowance of twenty-three vitamins and minerals in another county starting ≤24 weeks of gestation and continuing until delivery. Compared with the FA group, prenatal supplementation with MMN was significantly associated with reduced odds of anaemia in the third trimester. This was demonstrated in the primary outcome, with an adjusted OR (AOR) of 0·63; 95 % CI 0·45, 0·88 and P=0·007 and also reduced odds of preterm delivery (AOR: 0·31; 95 % CI 0·15, 0·61; P=0·001). There was no difference between MMN and FA groups in mean birth weight (adjusted mean difference: 36·78; 95 % CI -19·42, 92·98 g; P=0·200), whereas MMN supplementation significantly reduced the odds of low-birth weight (LBW) babies (AOR: 0·58; 95 % CI 0·36, 0·91; P=0·019). In conclusion, the antenatal MMN supplementation in rural Tibet is associated with a reduction of maternal anaemia in the third trimester, and may potentially decrease the risk of preterm delivery and LBW babies.


Subject(s)
Anemia, Iron-Deficiency/prevention & control , Dietary Supplements , Micronutrients/administration & dosage , Pregnancy Outcome , Premature Birth/prevention & control , Adult , Birth Weight , China , Female , Folic Acid/administration & dosage , Follow-Up Studies , Humans , Infant, Low Birth Weight/growth & development , Logistic Models , Pregnancy , Pregnancy Trimester, Third , Prospective Studies , Risk Factors , Rural Population , Socioeconomic Factors , Young Adult
4.
Neurol Med Chir (Tokyo) ; 52(9): 646-8, 2012.
Article in English | MEDLINE | ID: mdl-23006878

ABSTRACT

A 14-year-old girl presented with a rare case of spontaneous bilateral supratentorial epidural hematomas which developed rapidly following cervical surgery. The hematomas presumably resulted from dural dynamics changes secondary to cerebrospinal fluid loss and intracranial hypotension. Intracranial epidural hemorrhage after spinal surgery is extremely uncommon with only one previous case report. Spontaneous intracranial epidural hematoma is an extremely rare complication, but should be considered as a possible complication of spine surgery, especially in adolescents complicated by delayed consciousness and breathing restoration from anesthesia. This case report expands the presently known clinical spectrum of this uncommon complication.


Subject(s)
Arachnoid/surgery , Decompression, Surgical , Hematoma, Epidural, Cranial/etiology , Meningeal Neoplasms/surgery , Neurilemmoma/surgery , Postoperative Complications/etiology , Spinal Cord Compression/surgery , Adolescent , Amnesia/etiology , Arachnoid Cysts/complications , Arachnoid Cysts/surgery , Brain Infarction/etiology , Cervical Vertebrae , Craniotomy , Delayed Emergence from Anesthesia/etiology , Dura Mater/injuries , Female , Gait Disorders, Neurologic/etiology , Hematoma, Epidural, Cranial/physiopathology , Hematoma, Epidural, Cranial/surgery , Hemostasis, Surgical , Humans , Hyperbaric Oxygenation , Hypoxia, Brain/etiology , Hypoxia, Brain/therapy , Intracranial Hypotension/etiology , Magnetic Resonance Imaging , Meningeal Neoplasms/complications , Neurilemmoma/complications , Paresis/etiology , Postoperative Complications/physiopathology , Postoperative Complications/surgery , Respiration, Artificial , Spinal Cord Compression/etiology
SELECTION OF CITATIONS
SEARCH DETAIL